3 results
Primary:* To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in subjects with moderately to severely active UC who achieved clinical response at Week 6 following administration of vedolizumab IV at Weeks 0…
Primary objective:* To assess the effect of vedolizumab SC maintenance treatment on clinical remission at Week 52 in subjects with moderately to severely active CD who achieved clinical response at Week 6 following administration of vedolizumab IV…
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 60 mgor 100 mg versus placebo for 12 weeks on the percent change from baseline in low-densitylipoprotein cholesterol (LDL-C) in patients with HeFH.The…